Big pharmas need to collaborate to boost declining R&D returns
This article was originally published in Scrip
Research heads in big pharma companies need to look at how to improve the return on investment of the R&D budgets if they are going to maintain their share of company spending. In its annual review of the R&D returns of the leading 12 pharma companies, Deloitte, the international professional services company, concludes that the industry needs to take a more innovative approach through collaborations if it is to deliver improved R&D returns.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.